Zulvac SBV


Inactivated Schmallenberg virus, strain BH80/11-4

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Zulvac SBV. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Zulvac SBV.

For practical information about using Zulvac SBV, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 11/03/2020

Authorisation details

Product details
Zulvac SBV
Agency product number
Active substance
Inactivated Schmallenberg virus, strain BH80/11-4
International non-proprietary name (INN) or common name
Inactivated Schmallenberg virus, strain BH80/11-4
  • Cattle
  • Sheep
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

15/01/2020 Zulvac SBV - EMEA/V/C/002781 - R/0007

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for bovidae
  • Inactivated viral vaccines

Therapeutic indication

For active immunisation of cattle and sheep from 3.5 months of age to prevent viraemia associated with infection by Schmallenberg virus.

Assessment history

How useful was this page?

Add your rating
1 rating